Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Eli Lilly (LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to ...

The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.

Kendall Markovic was a leader on and off the field when Hutchinson’s girls and boys soccer teams played host to Rockford Tuesday. The senior co-captain started as a mid-fielder, plus helped ...

Mozart Therapeutics, the leading developer of CD8 Treg network modulators in autoimmune disease, announces the presentation ...

This initiative, funded by the Innovative Health Initiative Joint Undertaking (IHI JU) with over EUR 38 million, aims to transform Crohn’s Disease from an incurable condition to one that can be ...

The following is a summary of “Mechanistic implications of the Mediterranean diet in patients with newly diagnosed Crohn's disease- multi-omic results from a prospective cohort,” published in the ...

The coprimary endpoints were the percentage of adult participants achieving clinical remission (defined as Crohn Disease Activity Index [CDAI] score <150) and endoscopic response (defined as >50% ...

One tool doctors use is called the Crohn’s Disease Activity Index (CDAI). A CDAI score is based on the severity of various symptoms over seven days. Those symptoms include things such as ...

Takeda and the EU’s Innovative Health Initiative have announced a €‎38m project aimed at improving early intervention in Crohn’s disease. The “first-of-its-kind” INTERCEPT study will use biomarkers to ...